Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.
EP: 1.Patient Case: A 56-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer and Visceral Metastases
EP: 2.Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
EP: 3.The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
EP: 4.Review of EMERALD Subgroup Analysis Data From SABCS 2023
EP: 5.Selecting a Second-Line Therapy for a Patient With HR+/HER2- mBC After Progression on ET + CDK4/6i Therapy
EP: 6.Management Approaches for HR+/HER2- mBC Based on Metastasis Location and Disease Burden
EP: 7.Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
EP: 8.Future Directions in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
